Skip to content
Clinical Evidence
PAD
PAD
DETOUR System
DETOUR System Evidence
DETOUR System Resources
DETOUR System Reimbursement
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Procedural Training
For Patients
About Us
About Us
News
The Team
Careers
External Jobs
Internal Jobs
Contact Us
Clinical Evidence
PAD
PAD
DETOUR System
DETOUR System Evidence
DETOUR System Resources
DETOUR System Reimbursement
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Procedural Training
For Patients
About Us
About Us
News
The Team
Careers
External Jobs
Internal Jobs
Contact Us
Search
Back to News
November 15, 2017
VEITH 2017 Presentation: Status of the LEOPARD Trial: Comparing the AFX Endologix Graft to other Standard EVAR Endografts
Prev
Previous
Endologix Appoints John Onopchenko as Chief Operating Officer
Next
Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Next
